TS
VTVT icon

Thomas Steyer’s vTv Therapeutics VTVT Stock Holding History

Thomas Steyer’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,709
Closed -$353K – 72
2016
Q1 		$353K Sell
1,709
-4,541
-73% -$1.13M ﹤0.01% 74
2015
Q4 		$1.7M Hold
6,250
– – 0.02% 67
2015
Q3 		$1.63M Buy
+6,250
New +$2.18M 0.02% 78

Other funds holding VTVT

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Thomas Steyer's VTVT Position: Q2 2016 in Review

Thomas Steyer sold out of vTv Therapeutics (VTVT) in Q2 2016, closing a stake of 1,709 shares — an estimated $353K sold.

Thomas Steyer first reported a position in VTVT in Q3 2015 and held it in 3 quarters. The position peaked at $1.7M in Q4 2015. 35 funds tracked by Wall St. Rank hold VTVT as of Q2 2016.

  • Thomas Steyer reported no remaining vTv Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Thomas Steyer sold 1,709 vTv Therapeutics shares in Q2 2016, an estimated $353K.
  • Thomas Steyer first reported a position in vTv Therapeutics in Q3 2015 and held it in 3 quarters.
  • Thomas Steyer's vTv Therapeutics position peaked at $1.7M in Q4 2015.
  • 35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2016.

Based on Farallon Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.